Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBV NASDAQ:EQIX NYSE:JNJ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$259.10+0.8%$234.57$187.62▼$261.64$458.24B0.38.36 million shs4.19 million shsEQIXEquinix$1,084.24+4.9%$1,056.85$720.62▼$1,128.68$106.93B0.98532,211 shs782,912 shsJNJJohnson & Johnson$263.43+1.6%$242.71$164.23▼$269.43$634.06B0.248.12 million shs6.35 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+1.80%+6.34%+30.39%+36.12%EQIXEquinix0.00%+6.30%-0.31%-2.21%+36.18%JNJJohnson & Johnson0.00%+4.15%+7.55%+15.82%+55.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$259.10+0.8%$234.57$187.62▼$261.64$458.24B0.38.36 million shs4.19 million shsEQIXEquinix$1,084.24+4.9%$1,056.85$720.62▼$1,128.68$106.93B0.98532,211 shs782,912 shsJNJJohnson & Johnson$263.43+1.6%$242.71$164.23▼$269.43$634.06B0.248.12 million shs6.35 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie0.00%+1.80%+6.34%+30.39%+36.12%EQIXEquinix0.00%+6.30%-0.31%-2.21%+36.18%JNJJohnson & Johnson0.00%+4.15%+7.55%+15.82%+55.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.84Moderate Buy$268.103.47% UpsideEQIXEquinix 2.88Moderate Buy$1,153.796.41% UpsideJNJJohnson & Johnson 2.80Moderate Buy$265.300.71% UpsideCurrent Analyst Ratings BreakdownLatest ABBV, EQIX, and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026JNJJohnson & Johnson Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)7/23/2026EQIXEquinix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)7/22/2026ABBVAbbVie Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$273.00 ➝ $282.007/17/2026JNJJohnson & Johnson GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$270.007/16/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Buy$280.007/16/2026JNJJohnson & Johnson ScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$305.007/16/2026JNJJohnson & Johnson Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$258.00 ➝ $265.007/16/2026JNJJohnson & Johnson Johnson RiceSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$261.007/16/2026JNJJohnson & Johnson The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$282.007/16/2026JNJJohnson & Johnson Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$284.00 ➝ $294.007/16/2026JNJJohnson & Johnson Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$263.00 ➝ $272.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$61.16B7.48$15.13 per share17.12($1.83) per share-141.58EQIXEquinix$9.22B11.60$34.80 per share31.16$144.15 per share7.52JNJJohnson & Johnson$97.93B6.48$14.12 per share18.66$33.85 per share7.78Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.23B$2.03127.6416.000.865.79%-576.45%13.39%7/31/2026 (Estimated)EQIXEquinix$1.35B$14.4575.0325.712.0115.07%10.03%3.60%7/29/2026 (Estimated)JNJJohnson & Johnson$26.80B$8.6330.5220.582.5021.48%32.86%13.41%10/13/2026 (Estimated)Latest ABBV, EQIX, and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2026Q2 2026ABBVAbbVie$3.61N/AN/AN/A$16.79 billionN/A7/29/2026Q2 2026EQIXEquinix$4.73N/AN/AN/A$2.59 billionN/A7/15/2026Q2 2026JNJJohnson & Johnson$2.84$2.90+$0.06$2.27$25.06 billion$25.31 billion4/29/2026Q1 2026ABBVAbbVie$2.59$2.65+$0.06$0.39$14.72 billion$15.00 billion4/29/2026Q1 2026EQIXEquinix$4.30$10.79+$6.49$4.20$2.52 billion$2.44 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.922.67%+6.80%340.89%53 YearsEQIXEquinix$20.641.90%+12.01%142.84%10 YearsJNJJohnson & Johnson$5.362.03%+5.25%62.11%64 YearsLatest ABBV, EQIX, and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/15/2026JNJJohnson & Johnsonquarterly$1.342.17%8/25/20268/25/20269/8/20266/18/2026ABBVAbbViequarterly$1.732.83%7/15/20267/15/20268/14/20264/29/2026EQIXEquinixquarterly$5.161.94%5/20/20265/20/20266/17/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVieN/A0.800.68EQIXEquinix1.391.181.18JNJJohnson & Johnson0.461.030.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%EQIXEquinix94.94%JNJJohnson & Johnson69.55%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.06%EQIXEquinix0.27%JNJJohnson & Johnson0.16%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie57,0001.77 billion1.77 billionOptionableEQIXEquinix13,71698.62 million98.36 millionOptionableJNJJohnson & Johnson138,2002.41 billion2.40 billionOptionableABBV, EQIX, and JNJ HeadlinesRecent News About These CompaniesOMERS ADMINISTRATION Corp Buys 38,472 Shares of Johnson & Johnson $JNJ2 hours ago | marketbeat.comBetter Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?2 hours ago | fool.comLombard Odier Asset Management Switzerland SA Has $33.05 Million Stake in Johnson & Johnson $JNJ2 hours ago | marketbeat.comLombard Odier Asset Management Europe Ltd Cuts Stake in Johnson & Johnson $JNJ2 hours ago | marketbeat.comWaverly Advisors LLC Buys 4,561 Shares of Johnson & Johnson $JNJ2 hours ago | marketbeat.comJohnson & Johnson $JNJ is London Co. of Virginia's 6th Largest Position3 hours ago | marketbeat.comPunch & Associates Investment Management Inc. Lowers Stock Holdings in Johnson & Johnson $JNJ3 hours ago | marketbeat.comBetter Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?3 hours ago | fool.comJohnson & Johnson $JNJ Shares Sold by Gabelli Funds LLCJuly 26 at 3:52 AM | marketbeat.comJim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened NextJuly 25 at 10:03 AM | finance.yahoo.comInsiders Shake Up TSMC, Johnson & Johnson, Strategy, Snap, 3MJuly 25 at 9:11 AM | tipranks.comJohnson & Johnson $JNJ Stock Holdings Decreased by Wealth Alliance LLCJuly 25 at 6:39 AM | marketbeat.comHealthcare of Ontario Pension Plan Trust Fund Purchases 281,192 Shares of Johnson & Johnson $JNJJuly 25 at 6:07 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Hilltop Holdings Inc.July 25 at 5:51 AM | marketbeat.comMorningstar Investment Management LLC Has $10.65 Million Stake in Johnson & Johnson $JNJJuly 25 at 5:43 AM | marketbeat.comJim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)’s Shares – Here’s What Happened NextJuly 25 at 5:31 AM | insidermonkey.comCumberland Partners Ltd Has $7.84 Million Position in Johnson & Johnson $JNJJuly 25 at 4:24 AM | marketbeat.comJohnson & Johnson $JNJ Shares Sold by Epoch Investment Partners Inc.July 25 at 4:23 AM | marketbeat.comCannell & Spears LLC Cuts Stake in Johnson & Johnson $JNJJuly 25 at 4:07 AM | marketbeat.comDai ichi Life Insurance Company Ltd Sells 20,668 Shares of Johnson & Johnson $JNJJuly 25 at 4:07 AM | marketbeat.comBollard Group LLC Increases Holdings in Johnson & Johnson $JNJJuly 25 at 3:22 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026Why Johnson & Johnson’s Earnings Dip Looks Like a Buying OpportunityBy Thomas Hughes | July 15, 2026Abivax: Wall Street Catches Up to the DataBy Chris Markoch | July 7, 2026ABBV, EQIX, and JNJ Company DescriptionsAbbVie NYSE:ABBV$259.10 +2.18 (+0.85%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$258.78 -0.32 (-0.12%) As of 07/24/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Equinix NASDAQ:EQIX$1,084.24 +50.69 (+4.90%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1,088.11 +3.87 (+0.36%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Equinix (Nasdaq: EQIX) is the world's digital infrastructure company . Digital leaders harness Equinix's trusted platform to bring together and interconnect foundational infrastructure at software speed. Equinix enables organizations to access all the right places, partners and possibilities to scale with agility, speed the launch of digital services, deliver world-class experiences and multiply their value, while supporting their sustainability goals.Johnson & Johnson NYSE:JNJ$263.43 +4.16 (+1.60%) Closing price 07/24/2026 03:59 PM EasternExtended Trading$263.30 -0.13 (-0.05%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
